Can a new pill prevent esophageal damage from returning?
NCT ID NCT07732075
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This trial tests whether an experimental drug called JP-1366 can prevent the return of erosive esophagitis in people whose condition has already healed. About 384 adults aged 19 to 75 will take either JP-1366 or the standard drug lansoprazole daily for 24 weeks. The goal is to see if JP-1366 is as effective as lansoprazole at keeping the esophagus healed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called JP-1366
- What this could lead to
- If effective, JP-1366 could offer a new maintenance option to prevent the return of esophageal damage in people with healed erosive esophagitis.
- What could go wrong
- This is a phase 3 non-inferiority trial, so JP-1366 may not prove better than the existing drug lansoprazole. Side effects and long-term safety are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EROSIVE ESOPHAGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart bottle cap could reveal hidden missed doses in GERD patients
- New GERD drug aims to heal esophagus damage when standard treatments fail
- Children's heartburn drug study halted early
- New GERD drug aims to keep esophagus healed, but trial never started
- New pill aims to heal Acid-Damaged esophagus
- Children's heartburn drug trial halted early – but data may still help